Luitpold Venofer NDA Adds Historical Control To Address FDA Concerns
This article was originally published in Pharmaceutical Approvals Monthly
Luitpold Pharmaceuticals addressed FDA concerns about baseline stability in pivotal trials for its injectable iron sucrose product Venofer by submitting historical control data, FDA review documents show.
You may also be interested in...
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011
The paradoxical finding that Dendreon's cancer immunotherapeutic Provenge (sipuleucel-T) improved overall survival in men with metastatic castration-resistant prostate cancer but did not appear to slow the progression of the disease is raising questions about the future of clinical development for the burgeoning class